Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a preservative-free formulation of Bimatoprost ophthalmic solution 0.01% YSBP compared to Lumigan49 bimatoprost ophthalmic solution 0.01% in adults with primary open-angle glaucoma POAG or ocular hypertension OH. The purpose is to establish whether YSBP is not less effective than Lumigan49 in lowering eye pressure in these patients. Participants will be randomly assigned to receive either YSBP or Lumigan49 eye drops. Both treatments contain bimatoprost 0.01%, and the study is designed as a double-blind, active-controlled, parallel-group trial. The treatment period lasts 12 weeks, during which participants will use the assigned eye drops as directed. During the study, participants will undergo regular eye pressure measurements, including the primary outcome of intra-ocular pressure at Week 12. Visual acuity and safety assessments will also be performed. Women of childbearing potential must use effective contraception. The study includes screening, a washout period for prior eye medications, treatment visits, and safety monitoring through the completion date in late 2027.